COMP <GO>
STOK vs JNJ // PIOTROSKI F-SCORE QUALITY
Stoke Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: STOK 2
— JNJ 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: JNJ
LAST: $26.35 (-0.23%) • MKT CAP: $1.70B
piotroski-score
6/9
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STOK VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STOK | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.10% | 25.50% | -31.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.64% | 2.97% | -0.33 | JNJ | /fcf-yield <GO> |
| Operating Margin | -11.20% | 34.70% | -45.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -3.70% | 28.50% | -32.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | STOK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.79 | 5.59 | +9.20 | STOK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.7 | 62.1 | -9.40 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.70B | $662.49B | -$660.79B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STOK REV | JNJ REV | STOK GROSS % | JNJ GROSS % | STOK FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $184.4M | $94.19B | — | 67.9% | $44.9M | $19.70B |
| FY 2024 | $36.6M | $88.82B | — | 69.1% | -$87.1M | $19.84B |
| FY 2023 | $8.8M | $85.16B | — | — | -$81.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STOK // BETA —
JNJ // BETA 1.08